Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | +31.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.49 | N/A | +31.94% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions impacting performance. They reiterated their commitment to long-term goals.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.
Nektar Therapeutics reported a wider-than-expected loss per share, which surprised analysts positively, but the lack of revenue data and overall market challenges led to a 4.72% decline in stock price. Investors may be cautious as the company navigates these difficulties without updated guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022